SG Americas Securities
FATE icon

SG Americas Securities’s Fate Therapeutics FATE Stock Holding History

SG Americas Securities’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$85K Sell
31,593
-48,546
-61% -$89.8K ﹤0.01% 3148
2026
Q1 		$96K Buy
80,139
+41,226
+106% +$50.2K ﹤0.01% 2945
2025
Q4 		$38K Buy
38,913
+24,013
+161% +$28.8K ﹤0.01% 3398
2025
Q3 		$19K Sell
14,900
-37,702
-72% -$40.6K ﹤0.01% 3291
2025
Q2 		$59K Buy
52,602
+18,100
+52% +$21K ﹤0.01% 2742
2025
Q1 		$27K Sell
34,502
-10,372
-23% -$12.7K ﹤0.01% 3350
2024
Q4 		$74K Buy
44,874
+10,511
+31% +$26.5K ﹤0.01% 2823
2024
Q3 		$120K Sell
34,363
-2,009
-6% -$7.82K ﹤0.01% 2916
2024
Q2 		$119K Sell
36,372
-1,084
-3% -$4.75K ﹤0.01% 2446
2024
Q1 		$275K Sell
37,456
-53,097
-59% -$329K ﹤0.01% 1747
2023
Q4 		$339K Buy
90,553
+16,911
+23% +$39.9K ﹤0.01% 1732
2023
Q3 		$156K Buy
+73,642
New +$244K ﹤0.01% 2472
2023
Q2 		– Sell
-11,000
Closed -$63K – 2555
2023
Q1 		$63K Buy
+11,000
New +$66.4K ﹤0.01% 3026
2022
Q3 		– Sell
-13,076
Closed -$324K – 3292
2022
Q2 		$324K Sell
13,076
-91,629
-88% -$2.53M ﹤0.01% 2335
2022
Q1 		$4.06M Sell
104,705
-315,485
-75% -$12.2M 0.03% 513
2021
Q4 		$24.6M Buy
420,190
+363,576
+642% +$20.6M 0.13% 109
2021
Q3 		$3.36M Buy
56,614
+3,543
+7% +$278K 0.02% 830
2021
Q2 		$4.61M Buy
53,071
+35,372
+200% +$2.85M 0.02% 634
2021
Q1 		$1.46M Buy
17,699
+14,820
+515% +$1.42M 0.01% 1266
2020
Q4 		$262K Sell
2,879
-74,392
-96% -$4.62M ﹤0.01% 2464
2020
Q3 		$3.09M Buy
77,271
+72,860
+1,652% +$2.54M 0.02% 520
2020
Q2 		$151K Sell
4,411
-21,024
-83% -$627K ﹤0.01% 3095
2020
Q1 		$565K Buy
+25,435
New +$643K 0.01% 1750
2019
Q2 		– Sell
-9,637
Closed -$169K – 3182
2019
Q1 		$169K Buy
+9,637
New +$152K ﹤0.01% 2687
2017
Q4 		– Sell
-10,596
Closed -$42K – 3324
2017
Q3 		$42K Buy
+10,596
New +$36K ﹤0.01% 3341

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

SG Americas Securities's FATE Position: Q2 2026 in Review

SG Americas Securities reduced its Fate Therapeutics (FATE) stake by 61% in Q2 2026, selling an estimated $89.8K and leaving 31,593 shares worth $85K. The position accounts for ﹤0.01% of the portfolio, ranked #3148.

SG Americas Securities first reported a position in FATE in Q3 2017 and has held it in 25 quarters since. The position peaked at $24.6M in Q4 2021. 155 funds tracked by Wall St. Rank hold FATE as of Q2 2026.

  • SG Americas Securities held 31,593 shares of Fate Therapeutics worth $85K as of Q2 2026.
  • SG Americas Securities sold 48,546 Fate Therapeutics shares in Q2 2026, an estimated $89.8K.
  • Fate Therapeutics made up ﹤0.01% of SG Americas Securities's portfolio in Q2 2026, its #3148 holding.
  • SG Americas Securities first reported a position in Fate Therapeutics in Q3 2017 and has held it in 25 quarters since.
  • SG Americas Securities's Fate Therapeutics position peaked at $24.6M in Q4 2021.
  • 155 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2026.

Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.